HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial

HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab

HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , American , Joern Aldag , Michael Kaiser , Hookipa Pharma Inc , Nasdaq , American Society Of Clinical Oncology , Pharma Inc , Drug Administration , University Of Chicago Medicine , Exchange Commission , European Society For Medical Oncology Annual Congress , Company Type , European Medicines Agency , Human Papillomavirus , American Society , Clinical Oncology , Chief Executive Officer , European Medicines , Neck Oncologist , Memorial Sloan Kettering Cancer Center , Sari Rosenberg , Principal Investigator , Fast Track Designation , European Society , Medical Oncology Annual Congress , Metastatic Head , Neck Squamous Cell Carcinoma , Updated Results , Private Securities Litigation Reform Act ,